Hackshaw MD, Bui CL, Ladner A, Tu N, Zahidu I, Ritchey ME, Salas M. Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumab post-trastuzumab gastric cancer. Cancer Treat Res Commun. 2020;24(2020). doi: 10.1016/j.ctarc.2020.100189
Domdey A, Njue A, Nuabor W, Lyall M, Heyes A, Elliott L. Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality. Eur Ann Allergy Clin Immunol. 2019 Jul;51(4):147-58. doi: 10.23822/EurAnnACI.1764-1489.100
Brown AL, Lupo PJ, Danysh HE, Okcu MF, Scheurer ME, Kamdar KY. Prevalence and predictors of overweight and obesity among a multiethnic population of pediatric acute lymphoblastic leukemia survivors: a cross-sectional assessment. J Pediatr Hematol Oncol. 2016 Aug;38(6):429-36. doi: 10.1097/MPH.0000000000000555
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.
Langagergaard V, Norgard B, Mellemkjaer L, Pendersen L, Rothman KJ, Sorensen HT. Seasonal variation in month of birth and diagnosis in children and adolescents with Hodgkin's disease and non-Hodgkin's lymphoma. J Pediatr Hematol Oncol. 2003 Jul;25(7):534-8.